Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SRPT

Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. alleging securities fraud related to the company's gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false statements regarding the safety of ELEVIDYS, concealing significant risks to patients [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to the halting of recruitment and dosing in trials, attracting regulatory scrutiny [2]. - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects [2]. Group 2: Investor Information - Investors who suffered losses during the specified period (June 22, 2023, to June 24, 2025) have until August 25, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].